Validated liquid chromatographic–fluorescence method for the quantitation of Darifenacin (cas 133099-04-4) in mice plasma and its application to a pharmacokinetic study
-
Add time:09/03/2019 Source:sciencedirect.com
A highly selective, sensitive, and rapid high-performance liquid chromatography (HPLC) method has been developed and validated for the quantification of Darifenacin (cas 133099-04-4) in mouse plasma. Bisoprolol was used as an internal standard (IS). Darifenacin and the IS were extracted using the deproteinisation technique, followed by injection of an aliquot of the supernatant into the chromatographic system. The chromatographic separation was achieved on a reversed phase C18 column with a mobile phase of acetonitrile: 0.1% diethyl amine (pH 3.5) (60:40, v/v) pumped at a flow rate of 1.0 mL min−1. The analytes were detected at 210 and 314 nm for excitation and emission, respectively. The assay exhibited a linear range of 100–3000 ng mL−1, with a lower detection limit of 35 ng mL−1. The method was statistically validated for linearity, accuracy, precision, selectivity and stability according to the FDA guidelines. The intra- and inter-assay coefficients of variation did not exceed 13.5% from the nominal concentration. The accuracy for darifenacin was within ±15% of the theoretical value. The assay was successfully applied in a pharmacokinetic study.
We also recommend Trading Suppliers and Manufacturers of Darifenacin (cas 133099-04-4). Pls Click Website Link as below: cas 133099-04-4 suppliers
Prev:Mouse aversion to isoflurane versus carbon dioxide gas
Next:Darifenacin (cas 133099-04-4)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ReviewDarifenacin (cas 133099-04-4), an M3 Selective Receptor Antagonist, is an Effective and Well-Tolerated Once-Daily Treatment for Overactive Bladder09/25/2019
- Female Urology—IncontinenceComparison of Darifenacin (cas 133099-04-4) and Oxybutynin in Patients with Overactive Bladder: Assessment of Ambulatory Urodynamics and Impact on Salivary Flow09/24/2019
- Neuro-urologyEffects of the M3 Receptor Selective Muscarinic Antagonist Darifenacin (cas 133099-04-4) on Bladder Afferent Activity of the Rat Pelvic Nerve09/10/2019
- Female Urology—IncontinenceTreatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin (cas 133099-04-4), an M3 Selective Receptor Antagonist09/09/2019
- In vivo demonstration of M3 muscarinic receptor subtype selectivity of Darifenacin (cas 133099-04-4) in mice09/08/2019
- Neuro-urologyDifferential Effects of the Antimuscarinic Agents Darifenacin (cas 133099-04-4) and Oxybutynin ER on Memory in Older Subjects09/07/2019
- Adult Urology: Voiding DysfunctionINCREASED WARNING TIME WITH Darifenacin (cas 133099-04-4): A NEW CONCEPT IN THE MANAGEMENT OF URINARY URGENCY09/06/2019
- Adult Urology: Voiding DysfunctionASSESSMENT OF COGNITIVE FUNCTION OF THE ELDERLY POPULATION: EFFECTS OF Darifenacin (cas 133099-04-4)09/05/2019
- Darifenacin (cas 133099-04-4)09/04/2019